Abstract: Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines.

Abstract: Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines.

Abstract: The present invention relates especially to a DNA fragment that is obtainable from the gene cluster within the genome of Streptomyces or Actinomyces that is responsible for staurosporin biosynthesis and that contains at least one gene or a part of a gene that codes for a polypeptide that is involved directly or indirectly in the biosynthesis of staurosporin and to methods of preparing said DNA fragment. The present invention relates furthermore to recombinant DNA molecules containing one of the DNA fragments according to the invention and to the plasmids and vectors derived therefrom. Also included are host organisms transformed with the said plasmid or vector DNA.

Abstract: The interaction between PP2Ac and eRF1 is described. The invention provides a method for identifying modulators of protein expression comprising screening for agents which affect the interaction between PP2A and eRF1, screening systems incorporating methods according to the invention and modulators of protein synthesis which target the eRF1-PP2A interaction.

Abstract: The invention relates to a compound of formula (I) ##STR1## Wherein: B is adenine, guanine or hypoxanthineZ is hydrogen or a negative chargeR is --[CH.sub.2 CH(R.sup.1)--O].sub.n -R.sup.2, --CH.sub.2 CH.sub.2 X, in whichR.sup.1 is hydrogen or (C.sub.1 -.sub.6) alkylR.sup.2 is hydrogen or (C.sub.1 -.sub.6) alkyln is a number from 1 to 6X is OH, F, NR.sup.3 R.sup.4R.sup.3 and R.sup.4 are independently from each other hydrogen or (C.sub.1 -.sub.6) alkyland to methods of enzymatically treating these compounds with biocatalysts having cyclic phosphodiesterase activity.

Abstract: The present invention relates to a process for the preparation of an oligomeric compound, comprising introduction of a lipophilic capping group to an unreacted reactive group, suitable for chain elongation, of a not elongated oligomeric compound intended to be elongated in a preceeding chain-elongation step, by reacting a lipophilic capping compound with said unreacted reactive group, which lipophilic capping group is not removable under the applied conditions of the synthesis and work-up of the oligomeric compound; and which not elongated oligomeric compound capped with said lipophilic capping group can be separated from said oligomeric compound on a hydrophobic stationary phase.

Abstract: A novel process for the production of heterologous proteins including the use of certain transformed protease deficient yeast strains is provided. The invention concerns also said transformed yeast strains and methods for the production thereof.

Abstract: A pharmaceutical composition comprising (A) an oligonucleotide 8 to 50 nucleotides in length, which is targeted to mRNA encoding human raf and is capable of inhibiting raf expression, entrapped in (B) sterically stabilized liposomes.

Abstract: The invention pertains to the field of recombinant DNA technology and concerns a method for the production of a protein heterologous to yeast in a homogeneous form with the aid of Saccharomyces cerevisiae strain HT393 or a derivative thereof carrying a hybrid vector containing the genes for said protein.

Abstract: A compound of formula (I) or salts thereof, where R.sup.0 is hydrogen or together with R.sup.7 O denotes a C.sub.1 -C.sub.15 hydrocarbylidenedioxy group, R.sup.1 is hydrogen, R.sup.1.sub.a or a group of formula (II), R.sup.1.sub.a is R.sup.1.sub.b or a protecting group Q, R.sup.1.sub.b is C.sub.1 -C.sub.20 alkyl, C.sub.2 -C.sub.20 alkenyl, C.sub.3 -C.sub.10 cycloalkyl, C.sub.6 -C.sub.15 aryl, C.sub.7 -C.sub.16 aralkyl or a 5- or 6-membered heterocyclic group attached by a carbon atom in the heterocyclic group to the indicated phosphorus atom, R.sup.2 is R.sup.2.sub.a or --OR.sup.15 or together with R.sup.5 denotes an oxy group --O--, provided that R.sup.2 is --OR.sup.15 when R.sup.1 is a group of formula (II), R.sup.2.sub.a is a C.sub.1 -C.sub.20 aliphatic group, a C.sub.3 -C.sub.10 cycloaliphatic group, a C.sub.6 -C.sub.15 aromatic group, a C.sub.7 -C.sub.16 araliphatic group, or a 5- or 6-membered heterocyclic group attached by a carbon atom in the heterocyclic group to the indicated phosphorus atom, R.sup.

Abstract: The present invention relates to cyclic terpyridine-lanthanide complexes having 8 nitrogen atoms and 10 carbon atoms in the macrocycle and containing a functional group in the terpyridine moiety. The invention also relates to a process for the preparation of cyclic terpyridine-lanthanide complexes through the condensation of terpyridine hydrazines with pyridine-2,6-dialdehydes or -ketones. The compounds can be complexed with oligonculeotides and are useful in the sequence-specific cleavage of RNA.

Abstract: The present invention relates to novel inhibitors belonging to the family of antistasin-type serine proteinase inhibitors, to their isolation from the medical leech Hirudo medicinalis, to DNA sequences encoding the novel inhibitors, to variants obtained by recombinant DNA technology or peptide synthesis, pharmaceutical compositions containing the inhibitors, and to their use in diagnosis and therapy.

Abstract: A medical pressure-sensitive adhesive is provided, having a high steam permeability (at least 1100 g/(m.sup.2 .multidot.24 Hr) at a temperature of 37.degree. C. and an RH of 40%), and exhibiting such an appropriate adhesive strength as the dressing material coated with the pressure-sensitive adhesive is not easily peeled off and a wound is not inflicted on the skin when the dressing material is peeled from the skin, and also exhibiting durability of such an appropriate adhesive strength as well as an appropriate cohesive force. A medical pressure-sensitive adhesive, comprising a polymer containing above 50 wt % of a unit derived from an alkoxyalkyl acrylate, the Tg value of the homopolymer thereof being -35.degree. C. or less is also provided.